Clinical Trials on Respiratory Syncytial Virus Infections in Finland

Total 811 results

Pfizer

Recruiting

A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection

Respiratory Syncytial Virus Infection

United States, Japan, China, Canada
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

Respiratory Syncytial Virus Immunization

United States, Australia, Puerto Rico
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age

Respiratory Syncytial Virus

Canada, United Kingdom, Spain, Brazil, Sweden, Poland, Australia, Finland
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)

Respiratory Syncytial Virus Infection

United States, Argentina, Belgium, Canada, Chile, China, Colombia, Denmark, Finland, France, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Peru, Philippines, Poland, Romania, South Africa, Thailand, Turkey, United Kingdom
UMC Utrecht
University of Turku; University of Oxford; University of Edinburgh; Servizo Galego...

Active, not recruiting

RESCEU Study: Defining the Burden of Disease of Respiratory Syncytial Virus in Europe in Infants

Respiratory Syncytial Virus Infections | RSV Infection | RSV Bronchiolitis

United Kingdom, Netherlands, Finland, Spain
GlaxoSmithKline

Completed

A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women

Respiratory Syncytial Virus Infections

United States, Germany, Finland
GlaxoSmithKline

Withdrawn

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

Respiratory Syncytial Virus Infections

Finland, United States, Spain
ModernaTX, Inc.

Active, not recruiting

Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study

Respiratory Syncytial Virus

United States
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Prospective Surveillance of Respiratory Syncytial Virus Disease in Infants and Toddlers

Respiratory Syncytial Virus Infections

United States, Finland, Ghana, Honduras, India, Spain, Thailand
Novavax

Completed

A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults

Respiratory Syncytial Virus (RSV)

United States
Merck Sharp & Dohme LLC

Recruiting

Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

RSV Infection

United States, Australia, Canada, Chile, Colombia, Germany, Greece, Malaysia, Mexico, New Zealand, Puerto Rico, Singapore, South Africa, Spain, Taiwan, Turkey, United Kingdom, Japan, Peru, Hong Kong, France, Thailand, Finland, Hungary, ... and more
ModernaTX, Inc.

Active, not recruiting

A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

Respiratory Syncytial Virus

United States
ModernaTX, Inc.

Active, not recruiting

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Respiratory Syncytial Virus | Human Metapneumovirus

Spain, United Kingdom, Canada, Australia, United States, South Africa, Poland, Colombia, Argentina, Latvia, Panama
ModernaTX, Inc.

Active, not recruiting

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

Respiratory Syncytial Virus

United States, Panama
GlaxoSmithKline

Completed

Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

Respiratory Syncytial Virus Infections

Finland, Spain, United Kingdom, United States, Thailand, Brazil, Canada, Panama, Italy, Colombia, Mexico, Poland, Turkey
GlaxoSmithKline

Active, not recruiting

Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

Respiratory Syncytial Virus Infections

United States, Finland, Germany, Japan, Taiwan
ModernaTX, Inc.

Recruiting

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

Respiratory Syncytial Virus

Canada, United Kingdom, Japan, United States, Chile, Denmark, Panama, South Africa
GlaxoSmithKline

Terminated

A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers

Respiratory Syncytial Virus Infections

United States, Spain, Brazil, Canada, Finland, India, Italy, Panama, South Africa
GlaxoSmithKline

Completed

Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants

Respiratory Syncytial Virus Infections

United States, Spain, Canada, Finland, Panama, South Africa, New Zealand, Australia, France
ModernaTX, Inc.

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age

Respiratory Syncytial Virus

United States, Spain, Taiwan, Korea, Republic of, Singapore, Canada, Belgium, Finland, Japan, United Kingdom, Chile, New Zealand, South Africa, Australia, Puerto Rico, Argentina, Costa Rica, Poland, Bangladesh, Colombia, Germany, ... and more
Bavarian Nordic

Completed

MVA-BN-RSV Vaccine Trial

Respiratory Syncytial Virus Infections

United States, Germany
GlaxoSmithKline

Terminated

A Phase III Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers (GRACE)

Respiratory Syncytial Virus Infections

United States, Australia, France, Finland, Taiwan, Spain, Philippines, Mexico, Belgium, Italy, Panama, New Zealand, Thailand, Brazil, Canada, India, Colombia, Korea, Republic of, United Kingdom, South Africa, Argentina, Bangladesh, Dominican... and more
ModernaTX, Inc.

Active, not recruiting

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age (RSVictory)

Respiratory Syncytial Virus

United States
GlaxoSmithKline

Recruiting

A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

Respiratory Syncytial Virus Infections

United States, Australia, Italy, Spain, Belgium, Korea, Republic of, France, Canada, Finland, Taiwan, Thailand, Brazil, India, New Zealand, Germany, South Africa, Colombia, Panama, Philippines, Argentina, Bangladesh, Dominican Republic and more
GlaxoSmithKline

Completed

A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.

Respiratory Syncytial Virus Infections

Finland, Spain, Canada, United States, Korea, Republic of
AstraZeneca

Completed

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY) (MELODY)

Respiratory Syncytial Virus Infections

United States, Finland, Spain, Belgium, France, Korea, Republic of, Turkey, Austria, New Zealand, South Africa, Australia, Germany, Bulgaria, United Kingdom, Ukraine, Argentina, Czechia, Panama, Estonia, Lithuania, Poland, Japan, Co... and more
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above

Respiratory Syncytial Virus Infections

France, Finland, Belgium, Spain, United Kingdom
AstraZeneca

Completed

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

Respiratory Syncytial Virus Infections

United States, France, Italy, Spain, Belgium, Russian Federation, Poland, Turkey, New Zealand, Austria, Korea, Republic of, Germany, Hungary, Bulgaria, Ukraine, South Africa, Japan, Estonia, Lithuania, United Kingdom, Canada, Czechia and more
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above

Respiratory Syncytial Virus Infections

United States
Pfizer

Completed

A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age (PICASSO)

RESPIRATORY SYNCYTIAL VIRUS (RSV)

United States
MedImmune LLC

Completed

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Respiratory Syncytial Virus Infections

United States, France, Spain, Denmark, Australia, New Zealand, Israel, United Kingdom, Italy, Sweden, Germany, Hungary, Chile, Argentina, Austria, Brazil, Bulgaria, Canada, Czech Republic, Greece, Iceland, Poland, Russian Federation, ...
GlaxoSmithKline

Completed

A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk of Development of Wheeze and Asthma From 0 to 6 Years of Age

Respiratory Syncytial Virus

Finland, Thailand, United States, Canada, South Africa, Bangladesh, Argentina, Honduras
GlaxoSmithKline

Active, not recruiting

Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

Respiratory Syncytial Virus Infections

United States, Canada, Spain, Finland, Germany, Japan, Estonia, Belgium, South Africa, Korea, Republic of, Italy, Russian Federation, Australia, Mexico, United Kingdom, New Zealand, Poland
Regeneron Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

Respiratory Syncytial Virus Infections

United States, Australia, Bulgaria, Canada, Chile, Denmark, Finland, Germany, Hungary, Netherlands, New Zealand, Panama, Puerto Rico, South Africa, Spain, Sweden, Turkey, Ukraine, United Kingdom
Finnish Institute for Health and Welfare
Norwegian Institute of Public Health; Karolinska Institutet

Completed

Tobacco Use and COVID-19 Incidence in the Finnish General Population (Tobrisk-CoV)

Covid19 | SARS-CoV-2 Infection

Finland
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age

Respiratory Tract Infections | Respiratory Syncytial Viruses

United Kingdom, Finland, United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

Influenza, Human Prevention | Respiratory Syncytial Viruses Prevention

United States
Tampere University Hospital

Active, not recruiting

Nasal and Pulmonary Nitric Oxide Output in COVID-19 Infection

COVID-19 | SARS-CoV-2 Infection

Finland
MedImmune LLC

Completed

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants. (MEDI8897 Ph2b)

Respiratory Syncytial Virus Infections

United States, Canada, Finland, France, Italy, Spain, Belgium, Hungary, Turkey, United Kingdom, New Zealand, Brazil, South Africa, Australia, Bulgaria, Czechia, Poland, Estonia, Lithuania, Chile, Latvia, Sweden, Argentina
MedImmune LLC

Completed

Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants

Respiratory Syncytial Virus Infections

United States
Provention Bio, Inc.

Completed

PROtocol for Coxsackievirus VaccinE in Healthy VoluNTteers (PROVENT)

Viral; Infection, Coxsackie(Virus)

Finland
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previously Been Vaccinated With PandemrixTM

Influenza

Finland
Novartis Vaccines

Completed

Safety and Immunogenicity of 2 Commercially Available Influenza Vaccines in Children

Influenza

Finland
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold- Adapted (CAIV-T) in Healthy Children Attending Day Care Centers

Influenza

Finland
MedImmune LLC

Completed

Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine,(CAIV-T), in Children Who Attend Day Care. (Final Report Version 2.0)

Influenza

Finland
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Three Commercially Available Influenza Vaccines in Children Aged 6 to <36 Months

Influenza

Finland
Finnish Institute for Health and Welfare
Hospital District of Helsinki and Uusimaa

Recruiting

Immune Responses in Health Care Personnel

Influenza

Finland
Finnish Institute for Health and Welfare
RWTH Aachen University; University of Erfurt

Completed

Herd Immunity and Influenza Vaccine Uptake (HIIVU)

Influenza, Human

Finland
Finnish Institute for Health and Welfare

Completed

Evaluation of the Effectiveness of Vaccination With 2009 H1N1 Vaccines During Influenza Season 2010-11

Influenza Caused by the 2009 H1N1 Influenza Virus

Finland
Novartis Vaccines

Completed

Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 Study

FLU

Finland

Clinical Trials on Respiratory Syncytial Virus Infections in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations